BIOL 142 Lecture Notes - Lecture 24: Lac Repressor, Galactoside, Lac Operon

90 views9 pages

bluemosquito338

30 Apr 2018

School

Department

Course

Professor

For unlimited access to Class Notes, a Class+ subscription is required.

!"#$%&%'()*+",-&."/

Predict(the(effect(of(mutations(in(the(lactose(metabolism(genes(lacZ,(lacY,(and(

lacI(upon(the(ability(of(E.(coli(to(grow(on(XGal(indicator(plates

0"%"-&,(/,$""%&%'(&/()%"()1(-2"(3)/-(4)5"$167(5#8()1(&9"%-&18&%'(6%:%)5%(

'"%"/

○

Describe(the(role(of(repressor(proteins(in(the(negative(control(of(transcription.(

Explain(the(roles(of(inducer(molecules(and(operator(sequences(in(prokaryotic(

operon(function,(using(the(lac(operon(as(an(example.(

Explain(why(transcription(of(the(lac(operon(is(only(fully(activated(when(lactose(is(

available(and(when(glucose(is(scarce.

1.(The(three(E.(coli(genes(involved(in(lactose(metabolism(were(named(lacZ,(lacY,(and(

lacI.

7#,;<36-#%-/(7#,:(16%,-&)%#7(=<'#7#,-)/&9#/"

>#%?-('$)5()%(,67-6$"(47#-"/(5&-2()%78(7#,-)/"(#/(#(/6'#$(/)6$,"

○

>#%?-(,6-(/6'#$(&%-)(,)34)%"%-(4#$-/(1)$(16$-2"$(3"-#*)7&/3

○

7#,A<36-#%-/(7#,:(-2"(3"3*$#%"(4$)-"&%('#7#,-)/&9"(4"$3"#/"(#%9(/)(,#%%)-(

-$#%/4)$-(7#,-)/"(&%-)(-2"(,"77B

0#7#,-)/&9"(4"$3"#/"(&/(#(-$#%/3"3*$#%"(4$)-"&%(-2#-(#77)5/(7#,-)/"(-)(

,)3"(&%(#%9(*"(,6-(*8(C<0#7

○

>#%%)-('$)5()%(7#,-)/"(,)%-#&%&%'(47#-"/

○

7#,D<36-#%-/(#$"(,#77"9 constitutive*mutants *",#6/"(-2"8(4$)96,"(=<

'#7#,-)/&9#/"(#%9('#7#,-)/&9"(4"$3"#/"(even*when*lactose*is*absent.

7#,D("%,)9"/(1)$(#($"4$"//)$(4$)-"&%(-2#-(&%2&*&-/(7#,;(#%9(7#,A( "E4$"//&)%(

&%(-2"(#*/"%,"()1(7#,-)/"

○

F""9"9(1)$(7#,-)/"(3"-#*)7&/3

G2"(7#,;(#%9(7#,A('"%"/(,)9"(1)$(4$)-"&%/(&%.)7."9(&%(7#,-)/"(3"-#*)7&/3H(52&7"(-2"(

7#,D('"%"(4$)96,-(/"$."/(#($"'67#-)$8(16%,-&)%

D%(-2"(#*/"%,"()1(7#,-)/"H(-2"(7#,D('"%"(4$)96,-(/26-/(9)5%("E4$"//&)%()1(7#,;(

#%9(7#,AB(I2"%(7#,-)/"(&/(4$"/"%-H(2)5"."$H(-$#%/,$&4-&)%()1(7#,;(#%9(7#,A(&/(

&%96,"9B

J"3).#7()1(#($"4$"//)$()1(#('"%"($"/67-/(&%(#,-&.#-&)%()1("E4$"//&)%()1(-2#-(

'"%"K-2&/(&/(/&3&7#$(-)(6/"()1(#(L9)6*7"(%"'#-&."M(&%(7#%'6#'"B

N)6*7"(%"'#-&."(/&-6#-&)%

J"3).&%'(#($"4$"//)$(&/(#%(#,-&.#-&)%(/-"4(-)(#,-&.#-"("E4$"//&)%()1(

9)5%/-$"#3('"%"/

○

J"4$"//)$(&/(*"&%'($"4$"//"9

○

1. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,;<P"%,)9&%'(=<'#7#,-)/&9#/"Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(5&-2(

R<0#7(#%9(,)%-#&%&%'()%78('76,)/"S(

TQ(C76"(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

B)*White*bacterial*colonies*will*grow.*

OB,)7&(,#%?-(3#:"(#%8(C<'#7

○

U6-#%-(1)$(7#,;('"%"H(,#%?-("E4$"//(C<'#7H(,#%?-(,6-(-2"(R<'#7(&%9&,#-)$(98"(

-)(3#:"(-2"(*76"(4$",&4&-#-"(

○

>Q(F)(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

2. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,;<P"%,)9&%'(=<'#7#,-)/&9#/"Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(5&-2(

R<0#7(#%9(,)%-#&%&%'()%78(7#,-)/"S(

TQ(C76"(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

CQ(I2&-"(*#,-"$&#7( ,)7)%&"/(5&77('$)5B(

C)*No*bacterial*colonies*will*grow.*

>#%?-(4$),"//(7#,-)/"(*",#6/"(-2"8(,#%?-("E4$"//(C<'#7

○

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

3. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,D<P"%,)9&%'(#(7#,($"4$"//)$(4$)-"&%Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(

5&-2(R<0#7(#%9(,)%-#&%&%'()%78(7#,-)/"S(

A)*Blue*bacterial*colonies*will*grow.*

F)($"4$"//)$

○

>#%('$)5()%(47#-"/(5&-2()%78(7#,-)/"(

○

>"77/(5&77("E4$"//(C<0#7

○

CQ(I2&-"(*#,-"$&#7( ,)7)%&"/(5&77('$)5B(

>Q(F)(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

I)679(2#."(-)(2#."(,"77/()1(9&11"$"%-('"%)-84"/(

○

W"$"H(&-?/(-2"(/#3"(*#,-"$&#('$)5&%'(&%(9&11"$"%-(/4)-/(#77()."$(-2"(47#-"

○

>)7)%&"/(/2)679(#77(*"(-2"(/#3"(,)7)$

○

2.(Szilard(and(Monod(hypothesized(that(the(lacI(gene(codes(for(a(repressor(that(exerts(

negative(control(over(the(lacZ(and(lacY(genes.(

G2"8(284)-2"/&X"9(-2#-(-2"($"4$"//)$(5)679(bind*directly*to*the*DNA*on*or*

near*the*promoter 1)$(-2"(7#,;(#%9(7#,A('"%"/

PromoterY(#(NFT(/"Z6"%,"(%""9"9(1)$(JFT(4)783"$#/"(-)(428/&,#778(

&%-"$#,-(5&-2(NFT(-)(-$#%/,$&*"(#(3JFT(1$)3(#(NFT(-"347#-"

F""9"9(-)(#99$"//(52#-(&/(#('"%"()%(#(,2$)3)/)3"(#%9(

$",)'%&-&)%()1(52"$"(-)(&%-"$#,-(5&-2(NFT

FOON(#(4$)3)-"$(1)$('"%"("E4$"//&)%

C)-2(4$):#$8)-"(#%9("6:#$8)-"/(%""9(4$)3)-"$/(1)$(JFT(

4)783"$#/"(-)(:%)5(52#-(#('"%"(&/(#%9(52#-(-)(-$#%/,$&*"

F)-(-$#%/,$&*"9(-2"3/"7."/

○

G2)6'2-($"4$"//)$(36/-(*&%9(%"#$(4$)3)-"$(-)(*7),:(JFT(#,-&.&-8(

○

!#,-)/"(-2"%(5)679(&%-"$#,-(5&-2(-2"($"4$"//)$(&%(#(5#8(-2#-(3#:"/(-2"(

$"4$"//)$($"7"#/"( 1$)3(&-/(*&%9&%'(/&-"

U6/-(2#."(#(7#,-)/"(*&%9&%'(/&-"(

○

!#,-)/"(-26/(5)679(&%96,"(-$#%/,$&4-&)%(*8($"3).&%'(%"'#-&."(,)%-$)7B

J"4$"//)$(&/($"3)."9(1$)3(NFT#B

JFT(4)783"$#/"(,#%(42/8,&#778(&%-"$#,-(5&-2(NFT(#%9(9$&."(-2"(

"E4$"//&)%

F"'#-&."(,)%-$)7(-$#%/,$&4-&)%

I2"%($"'67#-)$8(4$)-"&%("%,)9"9(*8(7#,D(&/(*)6%9(-)(-2"(NFTH(&-(

*7),:/(-$#%/,$&4-&)%

4. D%(%"'#-&."(,)%-$)7()1(-$#%/,$&4-&)%H(#('"%"(&/(#,-&.#-"9(52"%(^^^^^B(

TQ(#(:&%#/"(#99/(#(42)/42#-"(-)(NFT(

CQ(7#,-)/"(&/(-$#%/4)$-"9(&%-)(-2"(,"77(

>Q(#($"'67#-)$8(4$)-"&%(*&%9/(-)(NFT(

D)*a*regulatory*protein*is*removed*from*DNA

5. I28(36/-(#(/3#77(#3)6%-()1(-2"(7#,;(#%9(7#,A('"%"/(#75#8/(*"("E4$"//"9(&%(OB(,)7&H(

"."%(&%(-2"(4$"/"%,"()1(-2"($"4$"//)$(,)9"9(1)$(*8(-2"(7#,D('"%"S(

W&%-Y(I2#-(9)"/(-2"(4$)-"&%(,)9"9(1)$(*8(-2"(7#,A('"%"(9)S

ANSWERY('"%"/()11"$(/)3"(_7"#:8_(7"."7/()1("E4$"//&)%(5&-2)6-(#%8(4)/&-&."(9$&.&%'()1(

"E4$"//&)%(

No(expression(means(low(expression

F""9(-)('"-(7#,-)/"(&%-)(-2"(,"77(-)($"3)."(#($"4$"//)$(-)($"3)."('"%"()1(

-2"($"4$"//)$(

○

J"1"$$"9(-)(#/(_%)("E4$"//&)%_(*6-(&-?/(%)-([``a(-$6"

D1(%)("E4$"//&)%($"#778(3"#%-(%)("E4$"//&)%H(-2"$"?/(%)(5#8(7#,-)/"(,#%(

'"-(&%-)(-2"(,"77(&%()$9"$(-)($"3)."(-2"("E4$"//&)%

○

!)5(7"."7/("%)6'2(-)(3#:"(47#/3#(3"3*$#%"(#(7&--7"( 3)$"(4"$3"#*7"(

○

F)(/-#-"(52"$"(#(%"'#-&."(,)%-$)7(4$)-"&%(*&%9/(-)(NFT(#%9(/-#8/(-2"$"(#77(-2"(

-&3"

>)%/"Z6"%,"()1(*&%9&%'(#%9($"7"#/&%'( &/(-2#-("."%(52"%(5"(-2&%:(-2"$"(/2)679(

*"(%)("E4$"//&)%H(-2"$"(&/(7)5(_7"#:8_("E4$"//&)%

]B(b#,)*(#%9(U)%)9(,)&%"9(-2"(-"$3()4"$)%(1)$(#(/"-()1(,))$9&%#-"78($"'67#-"9(

*#,-"$&#7('"%"/(-2#-(#$"(-$#%/,$&*"9(-)'"-2"$(&%-)()%"(3JFTB

c4"$#-)$(&/(52"$"(-2"(4$"//)$(5&77(*&%9

D%.)7."('$)64&%'(-)'"-2"$($"7#-"9('"%"/(6%9"$(-2"()4"$#%-(,)%-$)7()1(

$"'67#-)$8(NFT("7"3"%-/

○

C#,-"$&#(/"-(64()4"$)%/(52"$"(-2"('"%"/(#$"($"'67#-"9(-)'"-2"$(

○

G2"('$)64()1('"%"/(&%.)7."9(&%(7#,-)/"(3"-#*)7&/3(5#/(-26/(-"$3"9(-2"(lac*

operonB

!#-"$(#(1)6$-2('"%"H(,#77"9(7#,TH(5#/(9&/,)."$"9(-)(*"(4#$-()1(-2"(7#,()4"$)%B(

G2"(7#,T('"%"(,)9"/(1)$(-2"("%X83"(-$#%/#,"-87#/"

c4"$)%/(&%.)7."(#(,)77",-&)%()1(4$)-"&%("%,)9&%'('"%"/(@

G2"(7#,;H(7#,AH(#%9(7#,T('"%"/(#$"(-$#%/,$&*"9(-)'"-2"$(#%9(#$"(-26/(,))$9&%#-"78(

$"'67#-"9

d$)3)-"$(&/(52"$"(JFT(4)783"$#/"(5&77(*&%9(-)(-$#%/,$&*"(3JFT@

c4"$#-)$(&/(52"$"(4$"//)$(*&%9/

>$"#-"/(#(428/&,#7($)#9(*7),:(-)(-$#%/,$&*"(-2"('"%"/()1(-2"()4"$)%

○

G2"(7#,D(4$)-"&%(&/(#(7#,($"4$"//)$(4$)-"&%(-2#-(4$"."%-/(-$#%/,$&4-&)%()1(-2"(7#,(

)4"$)%(*8(*&%9&%'(-)(#(/&-"(,#77"9(-2"(operator P#%("E#347"()1(-$#%/,$&4-&)%#7(

,)%-$)7QB

!#,-)/"H(-2"(inducerH(*&%9/(9&$",-78(-)(-2"(7#,($"4$"//)$(4$)-"&%(P#%("E#347"()1(

4)/-<-$#%/7#-&)%#7(,)%-$)7Q(,#6/&%'(&-(-)($"7"#/"(1$)3(-2"()4"$#-)$(#%9("%9&%'(

%"'#-&."(,)%-$)7()1(-2"()4"$)%B

!#,()4"$)%(&/(#%(&%96,&*7"(/8/-"3(

○

C)-2(6/"(4$)3)-"$/H(*6-(#(6/"()1(,)33)%(4$)3)-"$(&/(#(4$):#$8)-&,(-2&%'

O6:#$8)-"/(e52"$"("#,2('"%"(2#/(&-/()5%(&%9&.&96#7(4$)3)-"$(,)%-$)7

>#%(1&%"(-6%"("E4$"//&)%()1("."$8('"%"(&1("."$8('"%"(&/(6%9"$(

,)%-$)7()1(&-/()5%(4$)3)-"$

○

T/()44)/"9(-)(&%(4$):#$8)-"/(52"$"("E4$"//&)%(5&77(*"(-2"(/#3"(1)$(#77(

-2"('"%"/(,)%-$)77"9(*8(-2#-(4$)3)-"$(

○

fB(D%(-2"(^^^^^^(P4$"/"%,"g#*/"%,"Q()1(7#,-)/"H(-2"(7#,(^^^^^^(*&%9/(-)(-2"(7#,(^^^^^^(

/&-"B(

TQ(4$"/"%,"h()4"$#-)$h($"4$"//)$(

CQ(4$"/"%,"h($"4$"//)$h(4$)3)-"$(

>Q(#*/"%,"h()4"$#-)$h(4$)3)-"$(

NQ(#*/"%,"h()4"$#-)$h($"4$"//)$(

E)*absence;*repressor;*operator

J"4$"//)$(&/(7#,D

○

4.(Recall(the(results(of(an(experiment(we(conducted(that(revealed(the(lac(operon(is(not(

transcribed(when(both(glucose(and(lactose(are(present

i6"/-&)%(1$)3(7#/-(,7#//Y(9)"/(OB(,)7&(,)%/63"(7#,-)/"(&1(*)-2(7#,-)/"(#%9(

'76,)/"(#$"(4$"/"%-

076,)/"Y(9)%?-("E4$"//&)%(*<'#7(*",#6/"(-2"$"?/(%)(7#,-)/"(#.#&7#*7"

○

!#,-)/"Y(,)7)%&"/(#$"(*76"(*",#6/"(-2"$"(&/(7#,-)/"(#.#&7#*7"(-)(-#:"()11(#(

$"4$"//)$(#%9(9$&."(C<'#7("E4$"//&)%(

○

076,)/"(#%9(7#,-)/"Y(+6/-(52&-"(,)7)%&"/h(&%9&,#-"/(OB(,)7&(&/(6/&%'('76,)/"(

&%/-"#9()1(7#,-)/"

○

G2"($"7#-&)%/2&4()1 cyclic*AMP*(cAMP)*and*glucose &/(#-(-2"(,"%-"$()1(-2&/($"/67-

,TUd(&/(#(,)336%&,#-&)%("%X83"(5&-2&%(,"77/

○

>Td(4$)96,"/(,TUd(

○

D%(OB(,)7&H('76,)/"(&%2&*&-/(>Td(*",#6/"(8)6(#7$"#98(2#."(#(7)-()1(TGd(1$)3(

'76,)/"

D%."$/"($"7#-&)%/2&4(*"-5""%('76,)/"(#%9(,TUd

W&'2('76,)/"H(7)5(,TUd(#%9(.&,"(."$/#

○

!)5('76,)/"(7"."7/(,#6/"("7".#-"9(7"."7/()1(,8,7&,(TUd(P,TUdQB@

G2"("%X83"(adenylyl*cyclase 4$)96,"/(,TUd(1$)3(TGd(#%9(&/(&%2&*&-"9(*8(

'76,)/"B

T%)-2"$(5#8(-)($"'67#-"(-$#%/,$&4-&)%(&/(-)(3#:"(-2"(4$)3)-"$(/"Z6"%,"()1(-2"(

)4"$)%(5)$:(3)$"("11&,&"%-78B(POSITIVE*CONTROL

I2"%('76,)/"(&/(7)5(#%9(,TUd(&/(2&'2H(,TUd(*&%9/(-)(#(4$)-"&%(,#77"9(-2"(

,#-#*)7&-"(#,-&.#-)$(4$)-"&%(P>TdQ

I2"%(,TUd(&/(2&'2(P'76,)/"(7)5QH(,TUd(*&%9/(-)(>Td(-)($"."#7(#(NFT(

*&%9&%'(/&-"(&%(-2"(>Td(4$)-"&%

○

G2"(>Tde,TUd(,)347"E(*&%9/(-2"(NFT(#-(#(>Td(*&%9&%'(/&-"(+6/-(64/-$"#3()1(

-2"(4$)3)-"$B

J"3)."(7#,($"4$"//)$/(1$)3(-2"()4"$#-)$(e$"3)."9(FO0TGDjO(>cFGJc!

○

>Td(-2"%(*&%9/(%"#$(4$)3)-"$

○

I2"%(>Td<,TUd(*&%9/(%"#$(#(4$)3)-"$H(&-(9$&."/("E4$"//&)%()1(7#,()4"$)%

○

C&%9&%'()1(-2&/(/&-"(#&9/(JFT(4)783"$#/"(-)(*&%9(-2"(4$)3)-"$(#%9(&%,$"#/"/(

-$#%/,$&4-&)%($#-"B

I2"%('76,)/"(&/(2&'2(P#%9(,TUd(7"."7/(#$"(7)5QH("."%(52"%(7#,-)/"(&/(#.#&7#*7"H(-2"(

7#,()4"$)%(1#&7/(-)(-$#%/,$&*"(1$"Z6"%-78B

D1(,TUd(7"."7/(#$"(7)5H(>Td(&/(%)-(#,-&."(#%9(-$#%/,$&4-&)%(&/(%)-(&%,$"#/"9B@

G2"(#3)6%-()1(,TUd(#%9(-2"($#-"()1(7#,(-$#%/,$&4-&)%(#$"(&nversely*related -)(

-2"(,)%,"%-$#-&)%()1('76,)/"B

F)(4$)3)-&)%()1(C<'#7(*",#6/"('76,)/"(&/(2&'2H(/)(,TUd(&/(7)5H(#%9(>Td(,#%?-(

4$)3)-"(C<'#7('"%"("E4$"//&)%

076,)/"(&%2&*&-/(,TUdH(7"#9&%'(7"."7/(-)(*"(7)5

○

F)-2&%'(-)(*&%9(-)(>Td

○

>Td(,#%%)-(*&%9(%"#$(-2"(4$)3)-"$

○

F)-2&%'(&/(-2"$"(-)(9$&."("E4$"//&)%()1(C<'#7

○

kB(A)6(+6/-(9$#%:(#(7#$'"('7#//()1(3&7:(#%9(-2"(7"."7()1(7#,-)/"(&%(8)6$(&%-"/-&%"/(&/(2&'2H(

52&7"(-2"(7"."7()1('76,)/"(&/(7)5B(W)5(5&77(-2&/(,)%9&-&)%(&%176"%,"(-2"(=<'#7#,-)/&9#/"(

#,-&.&-8()1(OB(,)7&(&%(8)6$(&%-"/-&%"/S(=<'#7#,-)/&9#/"(#,-&.&-8(5&77(*"Y(

TB(!)5H(*",#6/"(-2"(,TUd<>Td(,)347"E(5&77(*"(6%#*7"(-)(*&%9(-2"(>Td(*&%9&%'(

/&-"B(

CB(!)5H(*",#6/"(,TUd(7"."7/(&%(-2"(OB(,)7&(5&77(*"(."$8(2&'2B(

>B(W&'2H(*",#6/"('#7#,-)/&9"(4"$3"#/"(5&77()4"%(&%($"/4)%/"(-)(7)5('76,)/"(

7"."7/H(17))9&%'(-2"(,"77/(5&-2(7#,-)/"B(

D.*High,*because*the*functional*CAP*protein*will*bind*to*the*CAP*binding*site*

and*the*lac*repressor*will*not*bind*the*operator.*

!)-/()1(7#,-)/"(&%(3&7:H(OB(,)7&(&%('6-(5)679(2#."(2&'2(C<'#7(*",#6/"()1(7)5(

'76,)/"

○

>Td(5&77(*&%9(#%9(9$&."("E4$"//&)%

○

!#,($"4$"//)$(5&77(%)-(*"(*)6%9(-)(#%()4"$#-)$

○

OB(G2"(7"."7()1(=<'#7#,-)/&9#/"(#,-&.&-8(,#%%)-(*"(9"-"$3&%"9B

C",#6/"(4)/&-&."(#%9(%"'#-&."(,)%-$)7("7"3"%-/(#$"(/64"$&34)/"9H(-2"(7#,()4"$)%(&/(

)%78(16778(#,-&.#-"9(52"%(7#,-)/"(&/(#.#&7#*7"(#%9(52"%('76,)/"(&/(/,#$,"B

C",#6/"(4)/&-&."(#%9(%"'#-&."(,)%-$)7("7"3"%-/(#$"(/64"$&34)/"9H(-2"(7#,()4"$)%(&/(

)%78(16778(#,-&.#-"9(52"%(7#,-)/"(&/(#.#&7#*7"(#%9(52"%('76,)/"(&/(/,#$,"B

Prokaryotic*Gene*Regulation*II

l$&9#8H(T4$&7([]H(\`[m

[[Ynm(TU

Unlock document

This preview shows pages 1-3 of the document.
Unlock all 9 pages and 3 million more documents.

Already have an account? Log in

!"#$%&%'()*+",-&."/

Predict(the(effect(of(mutations(in(the(lactose(metabolism(genes(lacZ,(lacY,(and(

lacI(upon(the(ability(of(E.(coli(to(grow(on(XGal(indicator(plates

0"%"-&,(/,$""%&%'(&/()%"()1(-2"(3)/-(4)5"$167(5#8()1(&9"%-&18&%'(6%:%)5%(

'"%"/

○

Describe(the(role(of(repressor(proteins(in(the(negative(control(of(transcription.(2.

Explain(the(roles(of(inducer(molecules(and(operator(sequences(in(prokaryotic(

operon(function,(using(the(lac(operon(as(an(example.(

Explain(why(transcription(of(the(lac(operon(is(only(fully(activated(when(lactose(is(

available(and(when(glucose(is(scarce.

1.(The(three(E.(coli(genes(involved(in(lactose(metabolism(were(named(lacZ,(lacY,(and(

lacI.

7#,;<36-#%-/(7#,:(16%,-&)%#7(=<'#7#,-)/&9#/"

>#%?-('$)5()%(,67-6$"(47#-"/(5&-2()%78(7#,-)/"(#/(#(/6'#$(/)6$,"

○

>#%?-(,6-(/6'#$(&%-)(,)34)%"%-(4#$-/(1)$(16$-2"$(3"-#*)7&/3

○

7#,A<36-#%-/(7#,:(-2"(3"3*$#%"(4$)-"&%('#7#,-)/&9"(4"$3"#/"(#%9(/)(,#%%)-(

-$#%/4)$-(7#,-)/"(&%-)(-2"(,"77B

0#7#,-)/&9"(4"$3"#/"(&/(#(-$#%/3"3*$#%"(4$)-"&%(-2#-(#77)5/(7#,-)/"(-)(

,)3"(&%(#%9(*"(,6-(*8(C<0#7

○

>#%%)-('$)5()%(7#,-)/"(,)%-#&%&%'(47#-"/

○

7#,D<36-#%-/(#$"(,#77"9 constitutive*mutants *",#6/"(-2"8(4$)96,"(=<

'#7#,-)/&9#/"(#%9('#7#,-)/&9"(4"$3"#/"(even*when*lactose*is*absent.

7#,D("%,)9"/(1)$(#($"4$"//)$(4$)-"&%(-2#-(&%2&*&-/(7#,;(#%9(7#,A( "E4$"//&)%(

&%(-2"(#*/"%,"()1(7#,-)/"

○

F""9"9(1)$(7#,-)/"(3"-#*)7&/3@

G2"(7#,;(#%9(7#,A('"%"/(,)9"(1)$(4$)-"&%/(&%.)7."9(&%(7#,-)/"(3"-#*)7&/3H(52&7"(-2"(

7#,D('"%"(4$)96,-(/"$."/(#($"'67#-)$8(16%,-&)%

D%(-2"(#*/"%,"()1(7#,-)/"H(-2"(7#,D('"%"(4$)96,-(/26-/(9)5%("E4$"//&)%()1(7#,;(

#%9(7#,AB(I2"%(7#,-)/"(&/(4$"/"%-H(2)5"."$H(-$#%/,$&4-&)%()1(7#,;(#%9(7#,A(&/(

&%96,"9B

J"3).#7()1(#($"4$"//)$()1(#('"%"($"/67-/(&%(#,-&.#-&)%()1("E4$"//&)%()1(-2#-(

'"%"K-2&/(&/(/&3&7#$(-)(6/"()1(#(L9)6*7"(%"'#-&."M(&%(7#%'6#'"B

N)6*7"(%"'#-&."(/&-6#-&)%

J"3).&%'(#($"4$"//)$(&/(#%(#,-&.#-&)%(/-"4(-)(#,-&.#-"("E4$"//&)%()1(

9)5%/-$"#3('"%"/

○

J"4$"//)$(&/(*"&%'($"4$"//"9

○

1. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,;<P"%,)9&%'(=<'#7#,-)/&9#/"Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(5&-2(

R<0#7(#%9(,)%-#&%&%'()%78('76,)/"S(

TQ(C76"(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

B)*White*bacterial*colonies*will*grow.*

OB,)7&(,#%?-(3#:"(#%8(C<'#7

○

U6-#%-(1)$(7#,;('"%"H(,#%?-("E4$"//(C<'#7H(,#%?-(,6-(-2"(R<'#7(&%9&,#-)$(98"(

-)(3#:"(-2"(*76"(4$",&4&-#-"(

○

>Q(F)(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

2. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,;<P"%,)9&%'(=<'#7#,-)/&9#/"Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(5&-2(

R<0#7(#%9(,)%-#&%&%'()%78(7#,-)/"S(

TQ(C76"(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

CQ(I2&-"(*#,-"$&#7( ,)7)%&"/(5&77('$)5B(

C)*No*bacterial*colonies*will*grow.*

>#%?-(4$),"//(7#,-)/"(*",#6/"(-2"8(,#%?-("E4$"//(C<'#7

○

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

3. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,D<P"%,)9&%'(#(7#,($"4$"//)$(4$)-"&%Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(

5&-2(R<0#7(#%9(,)%-#&%&%'()%78(7#,-)/"S(

A)*Blue*bacterial*colonies*will*grow.*

F)($"4$"//)$

○

>#%('$)5()%(47#-"/(5&-2()%78(7#,-)/"(

○

>"77/(5&77("E4$"//(C<0#7

○

CQ(I2&-"(*#,-"$&#7( ,)7)%&"/(5&77('$)5B(

>Q(F)(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

I)679(2#."(-)(2#."(,"77/()1(9&11"$"%-('"%)-84"/(

○

W"$"H(&-?/(-2"(/#3"(*#,-"$&#('$)5&%'(&%(9&11"$"%-(/4)-/(#77()."$(-2"(47#-"

○

>)7)%&"/(/2)679(#77(*"(-2"(/#3"(,)7)$

○

2.(Szilard(and(Monod(hypothesized(that(the(lacI(gene(codes(for(a(repressor(that(exerts(

negative(control(over(the(lacZ(and(lacY(genes.(

G2"8(284)-2"/&X"9(-2#-(-2"($"4$"//)$(5)679(bind*directly*to*the*DNA*on*or*

near*the*promoter 1)$(-2"(7#,;(#%9(7#,A('"%"/

PromoterY(#(NFT(/"Z6"%,"(%""9"9(1)$(JFT(4)783"$#/"(-)(428/&,#778(

&%-"$#,-(5&-2(NFT(-)(-$#%/,$&*"(#(3JFT(1$)3(#(NFT(-"347#-"

F""9"9(-)(#99$"//(52#-(&/(#('"%"()%(#(,2$)3)/)3"(#%9(

$",)'%&-&)%()1(52"$"(-)(&%-"$#,-(5&-2(NFT

FOON(#(4$)3)-"$(1)$('"%"("E4$"//&)%

C)-2(4$):#$8)-"(#%9("6:#$8)-"/(%""9(4$)3)-"$/(1)$(JFT(

4)783"$#/"(-)(:%)5(52#-(#('"%"(&/(#%9(52#-(-)(-$#%/,$&*"

F)-(-$#%/,$&*"9(-2"3/"7."/

○

G2)6'2-($"4$"//)$(36/-(*&%9(%"#$(4$)3)-"$(-)(*7),:(JFT(#,-&.&-8(

○

!#,-)/"(-2"%(5)679(&%-"$#,-(5&-2(-2"($"4$"//)$(&%(#(5#8(-2#-(3#:"/(-2"(

$"4$"//)$($"7"#/"( 1$)3(&-/(*&%9&%'(/&-"

U6/-(2#."(#(7#,-)/"(*&%9&%'(/&-"(

○

!#,-)/"(-26/(5)679(&%96,"(-$#%/,$&4-&)%(*8($"3).&%'(%"'#-&."(,)%-$)7B

J"4$"//)$(&/($"3)."9(1$)3(NFT#B

JFT(4)783"$#/"(,#%(42/8,&#778(&%-"$#,-(5&-2(NFT(#%9(9$&."(-2"(

"E4$"//&)%

F"'#-&."(,)%-$)7(-$#%/,$&4-&)%

I2"%($"'67#-)$8(4$)-"&%("%,)9"9(*8(7#,D(&/(*)6%9(-)(-2"(NFTH(&-(

*7),:/(-$#%/,$&4-&)%

4. D%(%"'#-&."(,)%-$)7()1(-$#%/,$&4-&)%H(#('"%"(&/(#,-&.#-"9(52"%(^^^^^B(

TQ(#(:&%#/"(#99/(#(42)/42#-"(-)(NFT(

CQ(7#,-)/"(&/(-$#%/4)$-"9(&%-)(-2"(,"77(

>Q(#($"'67#-)$8(4$)-"&%(*&%9/(-)(NFT(

D)*a*regulatory*protein*is*removed*from*DNA

5. I28(36/-(#(/3#77(#3)6%-()1(-2"(7#,;(#%9(7#,A('"%"/(#75#8/(*"("E4$"//"9(&%(OB(,)7&H(

"."%(&%(-2"(4$"/"%,"()1(-2"($"4$"//)$(,)9"9(1)$(*8(-2"(7#,D('"%"S(

W&%-Y(I2#-(9)"/(-2"(4$)-"&%(,)9"9(1)$(*8(-2"(7#,A('"%"(9)S

ANSWERY('"%"/()11"$(/)3"(_7"#:8_(7"."7/()1("E4$"//&)%(5&-2)6-(#%8(4)/&-&."(9$&.&%'()1(

"E4$"//&)%(

No(expression(means(low(expression

F""9(-)('"-(7#,-)/"(&%-)(-2"(,"77(-)($"3)."(#($"4$"//)$(-)($"3)."('"%"()1(

-2"($"4$"//)$(

○

J"1"$$"9(-)(#/(_%)("E4$"//&)%_(*6-(&-?/(%)-([``a(-$6"

D1(%)("E4$"//&)%($"#778(3"#%-(%)("E4$"//&)%H(-2"$"?/(%)(5#8(7#,-)/"(,#%(

'"-(&%-)(-2"(,"77(&%()$9"$(-)($"3)."(-2"("E4$"//&)%

○

!)5(7"."7/("%)6'2(-)(3#:"(47#/3#(3"3*$#%"(#(7&--7"( 3)$"(4"$3"#*7"(

○

F)(/-#-"(52"$"(#(%"'#-&."(,)%-$)7(4$)-"&%(*&%9/(-)(NFT(#%9(/-#8/(-2"$"(#77(-2"(

-&3"

>)%/"Z6"%,"()1(*&%9&%'(#%9($"7"#/&%'( &/(-2#-("."%(52"%(5"(-2&%:(-2"$"(/2)679(

*"(%)("E4$"//&)%H(-2"$"(&/(7)5(_7"#:8_("E4$"//&)%

]B(b#,)*(#%9(U)%)9(,)&%"9(-2"(-"$3()4"$)%(1)$(#(/"-()1(,))$9&%#-"78($"'67#-"9(

*#,-"$&#7('"%"/(-2#-(#$"(-$#%/,$&*"9(-)'"-2"$(&%-)()%"(3JFTB

c4"$#-)$(&/(52"$"(-2"(4$"//)$(5&77(*&%9

D%.)7."('$)64&%'(-)'"-2"$($"7#-"9('"%"/(6%9"$(-2"()4"$#%-(,)%-$)7()1(

$"'67#-)$8(NFT("7"3"%-/

○

C#,-"$&#(/"-(64()4"$)%/(52"$"(-2"('"%"/(#$"($"'67#-"9(-)'"-2"$(

○

G2"('$)64()1('"%"/(&%.)7."9(&%(7#,-)/"(3"-#*)7&/3(5#/(-26/(-"$3"9(-2"(lac*

operonB

!#-"$(#(1)6$-2('"%"H(,#77"9(7#,TH(5#/(9&/,)."$"9(-)(*"(4#$-()1(-2"(7#,()4"$)%B(

G2"(7#,T('"%"(,)9"/(1)$(-2"("%X83"(-$#%/#,"-87#/"

c4"$)%/(&%.)7."(#(,)77",-&)%()1(4$)-"&%("%,)9&%'('"%"/(@

G2"(7#,;H(7#,AH(#%9(7#,T('"%"/(#$"(-$#%/,$&*"9(-)'"-2"$(#%9(#$"(-26/(,))$9&%#-"78(

$"'67#-"9

d$)3)-"$(&/(52"$"(JFT(4)783"$#/"(5&77(*&%9(-)(-$#%/,$&*"(3JFT@

c4"$#-)$(&/(52"$"(4$"//)$(*&%9/

>$"#-"/(#(428/&,#7($)#9(*7),:(-)(-$#%/,$&*"(-2"('"%"/()1(-2"()4"$)%

○

G2"(7#,D(4$)-"&%(&/(#(7#,($"4$"//)$(4$)-"&%(-2#-(4$"."%-/(-$#%/,$&4-&)%()1(-2"(7#,(

)4"$)%(*8(*&%9&%'(-)(#(/&-"(,#77"9(-2"(operator P#%("E#347"()1(-$#%/,$&4-&)%#7(

,)%-$)7QB

!#,-)/"H(-2"(inducerH(*&%9/(9&$",-78(-)(-2"(7#,($"4$"//)$(4$)-"&%(P#%("E#347"()1(

4)/-<-$#%/7#-&)%#7(,)%-$)7Q(,#6/&%'(&-(-)($"7"#/"(1$)3(-2"()4"$#-)$(#%9("%9&%'(

%"'#-&."(,)%-$)7()1(-2"()4"$)%B

!#,()4"$)%(&/(#%(&%96,&*7"(/8/-"3(

○

C)-2(6/"(4$)3)-"$/H(*6-(#(6/"()1(,)33)%(4$)3)-"$(&/(#(4$):#$8)-&,(-2&%'

O6:#$8)-"/(e52"$"("#,2('"%"(2#/(&-/()5%(&%9&.&96#7(4$)3)-"$(,)%-$)7

>#%(1&%"(-6%"("E4$"//&)%()1("."$8('"%"(&1("."$8('"%"(&/(6%9"$(

,)%-$)7()1(&-/()5%(4$)3)-"$

○

T/()44)/"9(-)(&%(4$):#$8)-"/(52"$"("E4$"//&)%(5&77(*"(-2"(/#3"(1)$(#77(

-2"('"%"/(,)%-$)77"9(*8(-2#-(4$)3)-"$(

○

fB(D%(-2"(^^^^^^(P4$"/"%,"g#*/"%,"Q()1(7#,-)/"H(-2"(7#,(^^^^^^(*&%9/(-)(-2"(7#,(^^^^^^(

/&-"B(

TQ(4$"/"%,"h()4"$#-)$h($"4$"//)$(

CQ(4$"/"%,"h($"4$"//)$h(4$)3)-"$(

>Q(#*/"%,"h()4"$#-)$h(4$)3)-"$(

NQ(#*/"%,"h()4"$#-)$h($"4$"//)$(

E)*absence;*repressor;*operator

J"4$"//)$(&/(7#,D

○

4.(Recall(the(results(of(an(experiment(we(conducted(that(revealed(the(lac(operon(is(not(

transcribed(when(both(glucose(and(lactose(are(present

i6"/-&)%(1$)3(7#/-(,7#//Y(9)"/(OB(,)7&(,)%/63"(7#,-)/"(&1(*)-2(7#,-)/"(#%9(

'76,)/"(#$"(4$"/"%-

076,)/"Y(9)%?-("E4$"//&)%(*<'#7(*",#6/"(-2"$"?/(%)(7#,-)/"(#.#&7#*7"

○

!#,-)/"Y(,)7)%&"/(#$"(*76"(*",#6/"(-2"$"(&/(7#,-)/"(#.#&7#*7"(-)(-#:"()11(#(

$"4$"//)$(#%9(9$&."(C<'#7("E4$"//&)%(

○

076,)/"(#%9(7#,-)/"Y(+6/-(52&-"(,)7)%&"/h(&%9&,#-"/(OB(,)7&(&/(6/&%'('76,)/"(

&%/-"#9()1(7#,-)/"

○

G2"($"7#-&)%/2&4()1 cyclic*AMP*(cAMP)*and*glucose &/(#-(-2"(,"%-"$()1(-2&/($"/67-

,TUd(&/(#(,)336%&,#-&)%("%X83"(5&-2&%(,"77/

○

>Td(4$)96,"/(,TUd(

○

D%(OB(,)7&H('76,)/"(&%2&*&-/(>Td(*",#6/"(8)6(#7$"#98(2#."(#(7)-()1(TGd(1$)3(

'76,)/"

D%."$/"($"7#-&)%/2&4(*"-5""%('76,)/"(#%9(,TUd

W&'2('76,)/"H(7)5(,TUd(#%9(.&,"(."$/#

○

!)5('76,)/"(7"."7/(,#6/"("7".#-"9(7"."7/()1(,8,7&,(TUd(P,TUdQB@

G2"("%X83"(adenylyl*cyclase 4$)96,"/(,TUd(1$)3(TGd(#%9(&/(&%2&*&-"9(*8(

'76,)/"B

T%)-2"$(5#8(-)($"'67#-"(-$#%/,$&4-&)%(&/(-)(3#:"(-2"(4$)3)-"$(/"Z6"%,"()1(-2"(

)4"$)%(5)$:(3)$"("11&,&"%-78B(POSITIVE*CONTROL

I2"%('76,)/"(&/(7)5(#%9(,TUd(&/(2&'2H(,TUd(*&%9/(-)(#(4$)-"&%(,#77"9(-2"(

,#-#*)7&-"(#,-&.#-)$(4$)-"&%(P>TdQ

I2"%(,TUd(&/(2&'2(P'76,)/"(7)5QH(,TUd(*&%9/(-)(>Td(-)($"."#7(#(NFT(

*&%9&%'(/&-"(&%(-2"(>Td(4$)-"&%

○

G2"(>Tde,TUd(,)347"E(*&%9/(-2"(NFT(#-(#(>Td(*&%9&%'(/&-"(+6/-(64/-$"#3()1(

-2"(4$)3)-"$B

J"3)."(7#,($"4$"//)$/(1$)3(-2"()4"$#-)$(e$"3)."9(FO0TGDjO(>cFGJc!

○

>Td(-2"%(*&%9/(%"#$(4$)3)-"$

○

I2"%(>Td<,TUd(*&%9/(%"#$(#(4$)3)-"$H(&-(9$&."/("E4$"//&)%()1(7#,()4"$)%

○

C&%9&%'()1(-2&/(/&-"(#&9/(JFT(4)783"$#/"(-)(*&%9(-2"(4$)3)-"$(#%9(&%,$"#/"/(

-$#%/,$&4-&)%($#-"B

I2"%('76,)/"(&/(2&'2(P#%9(,TUd(7"."7/(#$"(7)5QH("."%(52"%(7#,-)/"(&/(#.#&7#*7"H(-2"(

7#,()4"$)%(1#&7/(-)(-$#%/,$&*"(1$"Z6"%-78B

D1(,TUd(7"."7/(#$"(7)5H(>Td(&/(%)-(#,-&."(#%9(-$#%/,$&4-&)%(&/(%)-(&%,$"#/"9B@

G2"(#3)6%-()1(,TUd(#%9(-2"($#-"()1(7#,(-$#%/,$&4-&)%(#$"(&nversely*related -)(

-2"(,)%,"%-$#-&)%()1('76,)/"B

F)(4$)3)-&)%()1(C<'#7(*",#6/"('76,)/"(&/(2&'2H(/)(,TUd(&/(7)5H(#%9(>Td(,#%?-(

4$)3)-"(C<'#7('"%"("E4$"//&)%

076,)/"(&%2&*&-/(,TUdH(7"#9&%'(7"."7/(-)(*"(7)5

○

F)-2&%'(-)(*&%9(-)(>Td

○

>Td(,#%%)-(*&%9(%"#$(-2"(4$)3)-"$

○

F)-2&%'(&/(-2"$"(-)(9$&."("E4$"//&)%()1(C<'#7

○

kB(A)6(+6/-(9$#%:(#(7#$'"('7#//()1(3&7:(#%9(-2"(7"."7()1(7#,-)/"(&%(8)6$(&%-"/-&%"/(&/(2&'2H(

52&7"(-2"(7"."7()1('76,)/"(&/(7)5B(W)5(5&77(-2&/(,)%9&-&)%(&%176"%,"(-2"(=<'#7#,-)/&9#/"(

#,-&.&-8()1(OB(,)7&(&%(8)6$(&%-"/-&%"/S(=<'#7#,-)/&9#/"(#,-&.&-8(5&77(*"Y(

TB(!)5H(*",#6/"(-2"(,TUd<>Td(,)347"E(5&77(*"(6%#*7"(-)(*&%9(-2"(>Td(*&%9&%'(

/&-"B(

CB(!)5H(*",#6/"(,TUd(7"."7/(&%(-2"(OB(,)7&(5&77(*"(."$8(2&'2B(

>B(W&'2H(*",#6/"('#7#,-)/&9"(4"$3"#/"(5&77()4"%(&%($"/4)%/"(-)(7)5('76,)/"(

7"."7/H(17))9&%'(-2"(,"77/(5&-2(7#,-)/"B(

D.*High,*because*the*functional*CAP*protein*will*bind*to*the*CAP*binding*site*

and*the*lac*repressor*will*not*bind*the*operator.*

!)-/()1(7#,-)/"(&%(3&7:H(OB(,)7&(&%('6-(5)679(2#."(2&'2(C<'#7(*",#6/"()1(7)5(

'76,)/"

○

>Td(5&77(*&%9(#%9(9$&."("E4$"//&)%

○

!#,($"4$"//)$(5&77(%)-(*"(*)6%9(-)(#%()4"$#-)$

○

OB(G2"(7"."7()1(=<'#7#,-)/&9#/"(#,-&.&-8(,#%%)-(*"(9"-"$3&%"9B

C",#6/"(4)/&-&."(#%9(%"'#-&."(,)%-$)7("7"3"%-/(#$"(/64"$&34)/"9H(-2"(7#,()4"$)%(&/(

)%78(16778(#,-&.#-"9(52"%(7#,-)/"(&/(#.#&7#*7"(#%9(52"%('76,)/"(&/(/,#$,"B

C",#6/"(4)/&-&."(#%9(%"'#-&."(,)%-$)7("7"3"%-/(#$"(/64"$&34)/"9H(-2"(7#,()4"$)%(&/(

)%78(16778(#,-&.#-"9(52"%(7#,-)/"(&/(#.#&7#*7"(#%9(52"%('76,)/"(&/(/,#$,"B

Prokaryotic*Gene*Regulation*II

l$&9#8H(T4$&7([]H(\`[m [[Ynm(TU

Unlock document

This preview shows pages 1-3 of the document.
Unlock all 9 pages and 3 million more documents.

Already have an account? Log in

!"#$%&%'()*+",-&."/

Predict(the(effect(of(mutations(in(the(lactose(metabolism(genes(lacZ,(lacY,(and(

lacI(upon(the(ability(of(E.(coli(to(grow(on(XGal(indicator(plates

0"%"-&,(/,$""%&%'(&/()%"()1(-2"(3)/-(4)5"$167(5#8()1(&9"%-&18&%'(6%:%)5%(

'"%"/

○

Describe(the(role(of(repressor(proteins(in(the(negative(control(of(transcription.(2.

Explain(the(roles(of(inducer(molecules(and(operator(sequences(in(prokaryotic(

operon(function,(using(the(lac(operon(as(an(example.(

Explain(why(transcription(of(the(lac(operon(is(only(fully(activated(when(lactose(is(

available(and(when(glucose(is(scarce.

1.(The(three(E.(coli(genes(involved(in(lactose(metabolism(were(named(lacZ,(lacY,(and(

lacI.

7#,;<36-#%-/(7#,:(16%,-&)%#7(=<'#7#,-)/&9#/"

>#%?-('$)5()%(,67-6$"(47#-"/(5&-2()%78(7#,-)/"(#/(#(/6'#$(/)6$,"

○

>#%?-(,6-(/6'#$(&%-)(,)34)%"%-(4#$-/(1)$(16$-2"$(3"-#*)7&/3

○

7#,A<36-#%-/(7#,:(-2"(3"3*$#%"(4$)-"&%('#7#,-)/&9"(4"$3"#/"(#%9(/)(,#%%)-(

-$#%/4)$-(7#,-)/"(&%-)(-2"(,"77B

0#7#,-)/&9"(4"$3"#/"(&/(#(-$#%/3"3*$#%"(4$)-"&%(-2#-(#77)5/(7#,-)/"(-)(

,)3"(&%(#%9(*"(,6-(*8(C<0#7

○

>#%%)-('$)5()%(7#,-)/"(,)%-#&%&%'(47#-"/

○

7#,D<36-#%-/(#$"(,#77"9 constitutive*mutants *",#6/"(-2"8(4$)96,"(=<

'#7#,-)/&9#/"(#%9('#7#,-)/&9"(4"$3"#/"(even*when*lactose*is*absent.

7#,D("%,)9"/(1)$(#($"4$"//)$(4$)-"&%(-2#-(&%2&*&-/(7#,;(#%9(7#,A( "E4$"//&)%(

&%(-2"(#*/"%,"()1(7#,-)/"

○

F""9"9(1)$(7#,-)/"(3"-#*)7&/3@

G2"(7#,;(#%9(7#,A('"%"/(,)9"(1)$(4$)-"&%/(&%.)7."9(&%(7#,-)/"(3"-#*)7&/3H(52&7"(-2"(

7#,D('"%"(4$)96,-(/"$."/(#($"'67#-)$8(16%,-&)%

D%(-2"(#*/"%,"()1(7#,-)/"H(-2"(7#,D('"%"(4$)96,-(/26-/(9)5%("E4$"//&)%()1(7#,;(

#%9(7#,AB(I2"%(7#,-)/"(&/(4$"/"%-H(2)5"."$H(-$#%/,$&4-&)%()1(7#,;(#%9(7#,A(&/(

&%96,"9B

J"3).#7()1(#($"4$"//)$()1(#('"%"($"/67-/(&%(#,-&.#-&)%()1("E4$"//&)%()1(-2#-(

'"%"K-2&/(&/(/&3&7#$(-)(6/"()1(#(L9)6*7"(%"'#-&."M(&%(7#%'6#'"B

N)6*7"(%"'#-&."(/&-6#-&)%

J"3).&%'(#($"4$"//)$(&/(#%(#,-&.#-&)%(/-"4(-)(#,-&.#-"("E4$"//&)%()1(

9)5%/-$"#3('"%"/

○

J"4$"//)$(&/(*"&%'($"4$"//"9

○

1. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,;<P"%,)9&%'(=<'#7#,-)/&9#/"Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(5&-2(

R<0#7(#%9(,)%-#&%&%'()%78('76,)/"S(

TQ(C76"(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

B)*White*bacterial*colonies*will*grow.*

OB,)7&(,#%?-(3#:"(#%8(C<'#7

○

U6-#%-(1)$(7#,;('"%"H(,#%?-("E4$"//(C<'#7H(,#%?-(,6-(-2"(R<'#7(&%9&,#-)$(98"(

-)(3#:"(-2"(*76"(4$",&4&-#-"(

○

>Q(F)(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

2. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,;<P"%,)9&%'(=<'#7#,-)/&9#/"Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(5&-2(

R<0#7(#%9(,)%-#&%&%'()%78(7#,-)/"S(

TQ(C76"(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

CQ(I2&-"(*#,-"$&#7( ,)7)%&"/(5&77('$)5B(

C)*No*bacterial*colonies*will*grow.*

>#%?-(4$),"//(7#,-)/"(*",#6/"(-2"8(,#%?-("E4$"//(C<'#7

○

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

3. I2&,2()1(-2"(1)77)5&%'(/-#-"3"%-/(*"/-(9"/,$&*"/(-2"()6-,)3"(1$)3(,67-6$&%'(OB(

,)7&(36-#%-(1)$(7#,D<P"%,)9&%'(#(7#,($"4$"//)$(4$)-"&%Q()%(#'#$(&%9&,#-)$(47#-"/(,)#-"9(

5&-2(R<0#7(#%9(,)%-#&%&%'()%78(7#,-)/"S(

A)*Blue*bacterial*colonies*will*grow.*

F)($"4$"//)$

○

>#%('$)5()%(47#-"/(5&-2()%78(7#,-)/"(

○

>"77/(5&77("E4$"//(C<0#7

○

CQ(I2&-"(*#,-"$&#7( ,)7)%&"/(5&77('$)5B(

>Q(F)(*#,-"$&#7(,)7)%&"/(5&77('$)5B(

NQ(V)3"(*#,-"$&#7(,)7)%&"/(-2#-('$)5(5&77(*"(*76"(#%9()-2"$/(5&77(*"(52&-"B

I)679(2#."(-)(2#."(,"77/()1(9&11"$"%-('"%)-84"/(

○

W"$"H(&-?/(-2"(/#3"(*#,-"$&#('$)5&%'(&%(9&11"$"%-(/4)-/(#77()."$(-2"(47#-"

○

>)7)%&"/(/2)679(#77(*"(-2"(/#3"(,)7)$

○

2.(Szilard(and(Monod(hypothesized(that(the(lacI(gene(codes(for(a(repressor(that(exerts(

negative(control(over(the(lacZ(and(lacY(genes.(

G2"8(284)-2"/&X"9(-2#-(-2"($"4$"//)$(5)679(bind*directly*to*the*DNA*on*or*

near*the*promoter 1)$(-2"(7#,;(#%9(7#,A('"%"/

PromoterY(#(NFT(/"Z6"%,"(%""9"9(1)$(JFT(4)783"$#/"(-)(428/&,#778(

&%-"$#,-(5&-2(NFT(-)(-$#%/,$&*"(#(3JFT(1$)3(#(NFT(-"347#-"

F""9"9(-)(#99$"//(52#-(&/(#('"%"()%(#(,2$)3)/)3"(#%9(

$",)'%&-&)%()1(52"$"(-)(&%-"$#,-(5&-2(NFT

FOON(#(4$)3)-"$(1)$('"%"("E4$"//&)%

C)-2(4$):#$8)-"(#%9("6:#$8)-"/(%""9(4$)3)-"$/(1)$(JFT(

4)783"$#/"(-)(:%)5(52#-(#('"%"(&/(#%9(52#-(-)(-$#%/,$&*"

F)-(-$#%/,$&*"9(-2"3/"7."/

○

G2)6'2-($"4$"//)$(36/-(*&%9(%"#$(4$)3)-"$(-)(*7),:(JFT(#,-&.&-8(

○

!#,-)/"(-2"%(5)679(&%-"$#,-(5&-2(-2"($"4$"//)$(&%(#(5#8(-2#-(3#:"/(-2"(

$"4$"//)$($"7"#/"( 1$)3(&-/(*&%9&%'(/&-"

U6/-(2#."(#(7#,-)/"(*&%9&%'(/&-"(

○

!#,-)/"(-26/(5)679(&%96,"(-$#%/,$&4-&)%(*8($"3).&%'(%"'#-&."(,)%-$)7B

J"4$"//)$(&/($"3)."9(1$)3(NFT

JFT(4)783"$#/"(,#%(42/8,&#778(&%-"$#,-(5&-2(NFT(#%9(9$&."(-2"(

"E4$"//&)%

F"'#-&."(,)%-$)7(-$#%/,$&4-&)%

I2"%($"'67#-)$8(4$)-"&%("%,)9"9(*8(7#,D(&/(*)6%9(-)(-2"(NFTH(&-(

*7),:/(-$#%/,$&4-&)%

4. D%(%"'#-&."(,)%-$)7()1(-$#%/,$&4-&)%H(#('"%"(&/(#,-&.#-"9(52"%(^^^^^B(

TQ(#(:&%#/"(#99/(#(42)/42#-"(-)(NFT(

CQ(7#,-)/"(&/(-$#%/4)$-"9(&%-)(-2"(,"77(

>Q(#($"'67#-)$8(4$)-"&%(*&%9/(-)(NFT(

D)*a*regulatory*protein*is*removed*from*DNA

5. I28(36/-(#(/3#77(#3)6%-()1(-2"(7#,;(#%9(7#,A('"%"/(#75#8/(*"("E4$"//"9(&%(OB(,)7&H(

"."%(&%(-2"(4$"/"%,"()1(-2"($"4$"//)$(,)9"9(1)$(*8(-2"(7#,D('"%"S(

W&%-Y(I2#-(9)"/(-2"(4$)-"&%(,)9"9(1)$(*8(-2"(7#,A('"%"(9)S

ANSWERY('"%"/()11"$(/)3"(_7"#:8_(7"."7/()1("E4$"//&)%(5&-2)6-(#%8(4)/&-&."(9$&.&%'()1(

"E4$"//&)%(

No(expression(means(low(expression

F""9(-)('"-(7#,-)/"(&%-)(-2"(,"77(-)($"3)."(#($"4$"//)$(-)($"3)."('"%"()1(

-2"($"4$"//)$(

○

J"1"$$"9(-)(#/(_%)("E4$"//&)%_(*6-(&-?/(%)-([``a(-$6"

D1(%)("E4$"//&)%($"#778(3"#%-(%)("E4$"//&)%H(-2"$"?/(%)(5#8(7#,-)/"(,#%(

'"-(&%-)(-2"(,"77(&%()$9"$(-)($"3)."(-2"("E4$"//&)%

○

!)5(7"."7/("%)6'2(-)(3#:"(47#/3#(3"3*$#%"(#(7&--7"( 3)$"(4"$3"#*7"(

○

F)(/-#-"(52"$"(#(%"'#-&."(,)%-$)7(4$)-"&%(*&%9/(-)(NFT(#%9(/-#8/(-2"$"(#77(-2"(

-&3"

>)%/"Z6"%,"()1(*&%9&%'(#%9($"7"#/&%'( &/(-2#-("."%(52"%(5"(-2&%:(-2"$"(/2)679(

*"(%)("E4$"//&)%H(-2"$"(&/(7)5(_7"#:8_("E4$"//&)%

]B(b#,)*(#%9(U)%)9(,)&%"9(-2"(-"$3()4"$)%(1)$(#(/"-()1(,))$9&%#-"78($"'67#-"9(

*#,-"$&#7('"%"/(-2#-(#$"(-$#%/,$&*"9(-)'"-2"$(&%-)()%"(3JFTB

c4"$#-)$(&/(52"$"(-2"(4$"//)$(5&77(*&%9

D%.)7."('$)64&%'(-)'"-2"$($"7#-"9('"%"/(6%9"$(-2"()4"$#%-(,)%-$)7()1(

$"'67#-)$8(NFT("7"3"%-/

○

C#,-"$&#(/"-(64()4"$)%/(52"$"(-2"('"%"/(#$"($"'67#-"9(-)'"-2"$(

○

G2"('$)64()1('"%"/(&%.)7."9(&%(7#,-)/"(3"-#*)7&/3(5#/(-26/(-"$3"9(-2"(lac*

operonB

!#-"$(#(1)6$-2('"%"H(,#77"9(7#,TH(5#/(9&/,)."$"9(-)(*"(4#$-()1(-2"(7#,()4"$)%B(

G2"(7#,T('"%"(,)9"/(1)$(-2"("%X83"(-$#%/#,"-87#/"

c4"$)%/(&%.)7."(#(,)77",-&)%()1(4$)-"&%("%,)9&%'('"%"/(@

G2"(7#,;H(7#,AH(#%9(7#,T('"%"/(#$"(-$#%/,$&*"9(-)'"-2"$(#%9(#$"(-26/(,))$9&%#-"78(

$"'67#-"9

d$)3)-"$(&/(52"$"(JFT(4)783"$#/"(5&77(*&%9(-)(-$#%/,$&*"(3JFT@

c4"$#-)$(&/(52"$"(4$"//)$(*&%9/

>$"#-"/(#(428/&,#7($)#9(*7),:(-)(-$#%/,$&*"(-2"('"%"/()1(-2"()4"$)%

○

G2"(7#,D(4$)-"&%(&/(#(7#,($"4$"//)$(4$)-"&%(-2#-(4$"."%-/(-$#%/,$&4-&)%()1(-2"(7#,(

)4"$)%(*8(*&%9&%'(-)(#(/&-"(,#77"9(-2"(operator P#%("E#347"()1(-$#%/,$&4-&)%#7(

,)%-$)7QB

!#,-)/"H(-2"(inducerH(*&%9/(9&$",-78(-)(-2"(7#,($"4$"//)$(4$)-"&%(P#%("E#347"()1(

4)/-<-$#%/7#-&)%#7(,)%-$)7Q(,#6/&%'(&-(-)($"7"#/"(1$)3(-2"()4"$#-)$(#%9("%9&%'(

%"'#-&."(,)%-$)7()1(-2"()4"$)%B

!#,()4"$)%(&/(#%(&%96,&*7"(/8/-"3(

○

C)-2(6/"(4$)3)-"$/H(*6-(#(6/"()1(,)33)%(4$)3)-"$(&/(#(4$):#$8)-&,(-2&%'

O6:#$8)-"/(e52"$"("#,2('"%"(2#/(&-/()5%(&%9&.&96#7(4$)3)-"$(,)%-$)7

>#%(1&%"(-6%"("E4$"//&)%()1("."$8('"%"(&1("."$8('"%"(&/(6%9"$(

,)%-$)7()1(&-/()5%(4$)3)-"$

○

T/()44)/"9(-)(&%(4$):#$8)-"/(52"$"("E4$"//&)%(5&77(*"(-2"(/#3"(1)$(#77(

-2"('"%"/(,)%-$)77"9(*8(-2#-(4$)3)-"$(

○

fB(D%(-2"(^^^^^^(P4$"/"%,"g#*/"%,"Q()1(7#,-)/"H(-2"(7#,(^^^^^^(*&%9/(-)(-2"(7#,(^^^^^^(

/&-"B(

TQ(4$"/"%,"h()4"$#-)$h($"4$"//)$(

CQ(4$"/"%,"h($"4$"//)$h(4$)3)-"$(

>Q(#*/"%,"h()4"$#-)$h(4$)3)-"$(

NQ(#*/"%,"h()4"$#-)$h($"4$"//)$(

E)*absence;*repressor;*operator

J"4$"//)$(&/(7#,D

○

4.(Recall(the(results(of(an(experiment(we(conducted(that(revealed(the(lac(operon(is(not(

transcribed(when(both(glucose(and(lactose(are(present

i6"/-&)%(1$)3(7#/-(,7#//Y(9)"/(OB(,)7&(,)%/63"(7#,-)/"(&1(*)-2(7#,-)/"(#%9(

'76,)/"(#$"(4$"/"%-

076,)/"Y(9)%?-("E4$"//&)%(*<'#7(*",#6/"(-2"$"?/(%)(7#,-)/"(#.#&7#*7"

○

!#,-)/"Y(,)7)%&"/(#$"(*76"(*",#6/"(-2"$"(&/(7#,-)/"(#.#&7#*7"(-)(-#:"()11(#(

$"4$"//)$(#%9(9$&."(C<'#7("E4$"//&)%(

○

076,)/"(#%9(7#,-)/"Y(+6/-(52&-"(,)7)%&"/h(&%9&,#-"/(OB(,)7&(&/(6/&%'('76,)/"(

&%/-"#9()1(7#,-)/"

○

G2"($"7#-&)%/2&4()1 cyclic*AMP*(cAMP)*and*glucose &/(#-(-2"(,"%-"$()1(-2&/($"/67-

,TUd(&/(#(,)336%&,#-&)%("%X83"(5&-2&%(,"77/

○

>Td(4$)96,"/(,TUd(

○

D%(OB(,)7&H('76,)/"(&%2&*&-/(>Td(*",#6/"(8)6(#7$"#98(2#."(#(7)-()1(TGd(1$)3(

'76,)/"

D%."$/"($"7#-&)%/2&4(*"-5""%('76,)/"(#%9(,TUd

W&'2('76,)/"H(7)5(,TUd(#%9(.&,"(."$/#

○

!)5('76,)/"(7"."7/(,#6/"("7".#-"9(7"."7/()1(,8,7&,(TUd(P,TUdQB@

G2"("%X83"(adenylyl*cyclase 4$)96,"/(,TUd(1$)3(TGd(#%9(&/(&%2&*&-"9(*8(

'76,)/"B

T%)-2"$(5#8(-)($"'67#-"(-$#%/,$&4-&)%(&/(-)(3#:"(-2"(4$)3)-"$(/"Z6"%,"()1(-2"(

)4"$)%(5)$:(3)$"("11&,&"%-78B(POSITIVE*CONTROL

I2"%('76,)/"(&/(7)5(#%9(,TUd(&/(2&'2H(,TUd(*&%9/(-)(#(4$)-"&%(,#77"9(-2"(

,#-#*)7&-"(#,-&.#-)$(4$)-"&%(P>TdQ

I2"%(,TUd(&/(2&'2(P'76,)/"(7)5QH(,TUd(*&%9/(-)(>Td(-)($"."#7(#(NFT(

*&%9&%'(/&-"(&%(-2"(>Td(4$)-"&%

○

G2"(>Tde,TUd(,)347"E(*&%9/(-2"(NFT(#-(#(>Td(*&%9&%'(/&-"(+6/-(64/-$"#3()1(

-2"(4$)3)-"$B

J"3)."(7#,($"4$"//)$/(1$)3(-2"()4"$#-)$(e$"3)."9(FO0TGDjO(>cFGJc!

○

>Td(-2"%(*&%9/(%"#$(4$)3)-"$

○

I2"%(>Td<,TUd(*&%9/(%"#$(#(4$)3)-"$H(&-(9$&."/("E4$"//&)%()1(7#,()4"$)%

○

C&%9&%'()1(-2&/(/&-"(#&9/(JFT(4)783"$#/"(-)(*&%9(-2"(4$)3)-"$(#%9(&%,$"#/"/(

-$#%/,$&4-&)%($#-"B

I2"%('76,)/"(&/(2&'2(P#%9(,TUd(7"."7/(#$"(7)5QH("."%(52"%(7#,-)/"(&/(#.#&7#*7"H(-2"(

7#,()4"$)%(1#&7/(-)(-$#%/,$&*"(1$"Z6"%-78B

D1(,TUd(7"."7/(#$"(7)5H(>Td(&/(%)-(#,-&."(#%9(-$#%/,$&4-&)%(&/(%)-(&%,$"#/"9B@

G2"(#3)6%-()1(,TUd(#%9(-2"($#-"()1(7#,(-$#%/,$&4-&)%(#$"(&nversely*related -)(

-2"(,)%,"%-$#-&)%()1('76,)/"B

F)(4$)3)-&)%()1(C<'#7(*",#6/"('76,)/"(&/(2&'2H(/)(,TUd(&/(7)5H(#%9(>Td(,#%?-(

4$)3)-"(C<'#7('"%"("E4$"//&)%

076,)/"(&%2&*&-/(,TUdH(7"#9&%'(7"."7/(-)(*"(7)5

○

F)-2&%'(-)(*&%9(-)(>Td

○

>Td(,#%%)-(*&%9(%"#$(-2"(4$)3)-"$

○

F)-2&%'(&/(-2"$"(-)(9$&."("E4$"//&)%()1(C<'#7

○

kB(A)6(+6/-(9$#%:(#(7#$'"('7#//()1(3&7:(#%9(-2"(7"."7()1(7#,-)/"(&%(8)6$(&%-"/-&%"/(&/(2&'2H(

52&7"(-2"(7"."7()1('76,)/"(&/(7)5B(W)5(5&77(-2&/(,)%9&-&)%(&%176"%,"(-2"(=<'#7#,-)/&9#/"(

#,-&.&-8()1(OB(,)7&(&%(8)6$(&%-"/-&%"/S(=<'#7#,-)/&9#/"(#,-&.&-8(5&77(*"Y(

TB(!)5H(*",#6/"(-2"(,TUd<>Td(,)347"E(5&77(*"(6%#*7"(-)(*&%9(-2"(>Td(*&%9&%'(

/&-"B(

CB(!)5H(*",#6/"(,TUd(7"."7/(&%(-2"(OB(,)7&(5&77(*"(."$8(2&'2B(

>B(W&'2H(*",#6/"('#7#,-)/&9"(4"$3"#/"(5&77()4"%(&%($"/4)%/"(-)(7)5('76,)/"(

7"."7/H(17))9&%'(-2"(,"77/(5&-2(7#,-)/"B(

D.*High,*because*the*functional*CAP*protein*will*bind*to*the*CAP*binding*site*

and*the*lac*repressor*will*not*bind*the*operator.*

!)-/()1(7#,-)/"(&%(3&7:H(OB(,)7&(&%('6-(5)679(2#."(2&'2(C<'#7(*",#6/"()1(7)5(

'76,)/"

○

>Td(5&77(*&%9(#%9(9$&."("E4$"//&)%

○

!#,($"4$"//)$(5&77(%)-(*"(*)6%9(-)(#%()4"$#-)$

○

OB(G2"(7"."7()1(=<'#7#,-)/&9#/"(#,-&.&-8(,#%%)-(*"(9"-"$3&%"9B

C",#6/"(4)/&-&."(#%9(%"'#-&."(,)%-$)7("7"3"%-/(#$"(/64"$&34)/"9H(-2"(7#,()4"$)%(&/(

)%78(16778(#,-&.#-"9(52"%(7#,-)/"(&/(#.#&7#*7"(#%9(52"%('76,)/"(&/(/,#$,"B

C",#6/"(4)/&-&."(#%9(%"'#-&."(,)%-$)7("7"3"%-/(#$"(/64"$&34)/"9H(-2"(7#,()4"$)%(&/(

)%78(16778(#,-&.#-"9(52"%(7#,-)/"(&/(#.#&7#*7"(#%9(52"%('76,)/"(&/(/,#$,"B

Prokaryotic*Gene*Regulation*II

l$&9#8H(T4$&7([]H(\`[m [[Ynm(TU

Unlock document

This preview shows pages 1-3 of the document.
Unlock all 9 pages and 3 million more documents.

Already have an account? Log in

Document Summary

Predict the effect of mutations in the lactose metabolism genes lacz, lacy, and laci upon the ability of e. coli to grow on xgal indicator plates. Genetic screening is one of the most powerful way of identifying unknown genes. Describe the role of repressor proteins in the negative control of transcription. Explain the roles of inducer molecules and operator sequences in prokaryotic operon function, using the lac operon as an example. Can"t grow on culture plates with only lactose as a sugar source. Can"t cut sugar into component parts for further metabolism lacy- mutants lack the membrane protein galactoside permease and so cannot transport lactose into the cell. Galactoside permease is a transmembrane protein that allows lactose to come in and be cut by b-gal. The lacz and lacy genes code for proteins involved in lactose metabolism, while the laci gene product serves a regulatory function.

BIOL 142 Lecture Notes - Lecture 24: Lac Repressor, Galactoside, Lac Operon

Document Summary

Get access

Related Documents

BIOL 142 Lecture Notes - Lecture 8: Replica Plating, Lac Operon, Galactose

BIOL 142 Lecture Notes - Lecture 25: Lac Repressor, Lac Operon, Repressor

BIOL 142 Lecture Notes - Lecture 23: Replica Plating, Microrna, Gene Expression

Related Questions